FINWIRES · TerminalLIVE
FINWIRES

On's Continued Focus on Innovation, Performance to Drive Sales Growth, Earnings Beats, UBS Says

By

On's (ONON) continued focus on innovation, performance, athletes, sports, and direct-to-consumer selling while maintaining a premium brand position could deliver industry-leading sales growth and earnings beats, UBS Securities said Tuesday in a note.

UBS forecasts On recording 18%, 20%, and 29% of 5-year sales growth, adjusted EBITDA, and earnings per share compound annual growth rates, respectively, and expects strong growth to continue from there, according to the note.

The brand is gaining traction with younger customers, and its expansion within this demographic is an under-appreciated long-term growth driver, the brokerage said.

The company maintained its full-year sales growth guidance at 23%, despite delivering 26% top-line growth in Q1. UBS sees this as a sign of caution, given the macro uncertainty, rather than an indication of weaker demand in H2, the brokerage added.

On's nearly $0.1 Q1 earnings per share beat versus the UBS estimate drives most of the brokerage's $0.15 increase to its full-year EPS estimate, according to the note.

UBS kept a buy rating on On with a price target of $85.

Price: $35.52, Change: $+1.69, Percent Change: +5.00%

Related Articles

Wire

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.Gyre shares rose 1.4% in after-hours trading.

$GYRE
Wire

Evolution Petroleum Swings to Fiscal Q3 Loss as Revenue Falls; Shares Drop After Hours

Evolution Petroleum (EPM) reported a fiscal Q3 adjusted loss late Tuesday of $0.09 per diluted share, swinging from earnings of $0.02 a year earlier.Analysts polled by FactSet expected earnings of $0.02.Revenue in the three months ended March 31 fell to $20.2 million from $22.6 million a year earlier.Analysts surveyed by FactSet expected $21.3 million.Evolution shares fell 7.3% in after-hours trading.

$EPM
Wire

Arteris Q1 Adjusted Loss Narrows, Revenue Rises; Shares Gain After Hours; CFO to Retire

Arteris (AIP) reported a Q1 adjusted loss late Tuesday of $0.03 per diluted share, narrowing from the loss of $0.09 a year earlier.Four analysts polled by FactSet expected a loss of $0.07.Revenue in the three months ended March 31 rose to $22.9 million from $16.5 million a year earlier.Four analysts surveyed by FactSet expected $21 million.The company expects revenue of $23 million to $24 million in Q2 and $91 million to $95 million in the full year. Four analysts expect $22 million in Q2 and $91 million in the full year.Arteris shares rose 7.9% in after-hours trading.The company also said Chief Financial Officer Nicholas Hawkins plans to retire effective Aug. 31, and the board has started a search for a new CFO.

$AIP